© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 23, 1806-1811,
December 5, 2001
© 2001 Oxford University Press
REPORT |
Risk of Pneumonitis in Breast Cancer Patients Treated With Radiation Therapy and Combination Chemotherapy With Paclitaxel
Affiliations of authors: A. G. Taghian, S. I. Assaad, R. Schoenthaler, S. N. Powell (Department of Radiation Oncology), A. Niemierko (Departments of Radiation Oncology and Biostatistics), I. Kuter, J. Younger, M. Roche (Department of Medical Oncology), Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Correspondence to: Alphonse G. Taghian, M.D., Ph.D., Department of Radiation Oncology, Cox 3, Massachusetts General Hospital, Harvard Medical School, 100 Blossom St., Boston, MA 02114 (e-mail: ataghian{at}partners.org).
Background: Some chemotherapy (CT) drugs, including taxanes, may enhance the effectiveness of radiation therapy (RT). However, combining these therapies may increase the incidence of radiation pneumonitis, a lung inflammation. In a retrospective cohort study, we evaluated the incidence of radiation pneumonitis in breast cancer patients treated with RT and standard adjuvant CT by use of doxorubicin (Adriamycin) and cyclophosphamide, with and without paclitaxel. Methods: Forty-one patients with breast cancer were treated with RT and adjuvant CT, including paclitaxel. Paclitaxel and RT (to breast– chest wall in all and lymph nodes in some) were delivered sequentially in 20 patients and concurrently in 21 patients. Paclitaxel was given weekly in some patients and every 3 weeks in other patients. The incidence of radiation pneumonitis was compared with that among patients in our database whose treatments did not include paclitaxel (n = 1286). The percentage of the lung volume irradiated was estimated. The Cox proportional hazards model was used to find covariates that may be associated with the observed outcomes. All P values were two-sided. Results: Radiation pneumonitis developed in six of the 41 patients. Three patients received paclitaxel concurrently with RT, and three received it sequentially (P = .95). The mean percentage of lung volume irradiated was 20% in patients who developed radiation pneumonitis and 22% in those who did not (P = .6). For patients treated with CT including paclitaxel, the crude rate of developing radiation pneumonitis was 14.6% (95% confidence interval [CI] = 5.6% to 29.2%). For patients treated with CT without paclitaxel, the crude rate of pneumonitis was 1.1% (95% CI = 0.2% to 2.3%). The difference between the crude rates with or without paclitaxel is highly statistically significant (P<.0001). The mean time to develop radiation pneumonitis in patients treated concurrently with RT and paclitaxel was statistically significantly shorter in patients receiving paclitaxel weekly than in those receiving it every 3 weeks (P = .002). Conclusions: The use of paclitaxel and RT in the primary treatment of breast cancer should be undertaken with caution. Clinical trials with the use of combination CT, including paclitaxel plus RT, whether concurrent or sequential, must evaluate carefully the incidence of radiation pneumonitis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. H. Schmitz, A. R. Cappola, C. T. Stricker, C. Sweeney, and S. A. Norman The Intersection of Cancer and Aging: Establishing the Need for Breast Cancer Rehabilitation Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 866 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Taghian, J.-H. Jeong, E. P. Mamounas, D. S. Parda, M. Deutsch, J. P. Costantino, and N. Wolmark Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials J. Clin. Oncol., August 20, 2006; 24(24): 3927 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Chakravarthy, M. C. Kelley, B. McLaren, C. I. Truica, D. Billheimer, I. A. Mayer, A. M. Grau, D. H. Johnson, J. F. Simpson, R. D. Beauchamp, et al. Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Pinto, G. M. Frierson, C. Rabin, J. J. Trunzo, and B. H. Marcus Home-Based Physical Activity Intervention for Breast Cancer Patients J. Clin. Oncol., May 20, 2005; 23(15): 3577 - 3587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Pierce The Use of Radiotherapy After Mastectomy: A Review of the Literature J. Clin. Oncol., March 10, 2005; 23(8): 1706 - 1717. [Full Text] [PDF]
|
|
|
|
|
|
C. I. Sartor, B. L. Peterson, S. Woolf, T. J. FitzGerald, F. Laurie, A. J. Turrisi, J. Bogart, I. C. Henderson, and L. Norton Effect of Addition of Adjuvant Paclitaxel on Radiotherapy Delivery and Locoregional Control of Node-Positive Breast Cancer: Cancer and Leukemia Group B 9344 J. Clin. Oncol., January 1, 2005; 23(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-K. Yu, G. J. Whitman, H. D. Thames, A. U. Buzdar, E. A. Strom, G. H. Perkins, N. R. Schechter, M. D. McNeese, S.-W. Kau, E. S. Thomas, et al. Clinically Relevant Pneumonitis After Sequential Paclitaxel-Based Chemotherapy and Radiotherapy in Breast Cancer Patients J Natl Cancer Inst, November 17, 2004; 96(22): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hasegawa, S. Takanashi, K. Okudera, M. Aoki, K. Basaki, H. Kondo, T. Takahata, N. Yasui-Furukori, T. Tateishi, Y. Abe, et al. Weekly Paclitaxel and Nedaplatin With Concurrent Radiotherapy for Locally Advanced Non-small-cell Lung Cancer: a Phase I/II Study Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 647 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Taghian, J.-H. Jeong, E. Mamounas, S. Anderson, J. Bryant, M. Deutsch, and N. Wolmark Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials J. Clin. Oncol., November 1, 2004; 22(21): 4247 - 4254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Truong, I. A. Olivotto, T. J. Whelan, and M. Levine Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy Can. Med. Assoc. J., April 13, 2004; 170(8): 1263 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Kachnic and S. N. Powell Can ICAM Modulation Prevent Lung Injury From Ionizing Radiation? J Natl Cancer Inst, May 15, 2002; 94(10): 704 - 705. [Full Text] [PDF]
|
|